BE2016C021I2 - - Google Patents

Download PDF

Info

Publication number
BE2016C021I2
BE2016C021I2 BE2016C021C BE2016C021C BE2016C021I2 BE 2016C021 I2 BE2016C021 I2 BE 2016C021I2 BE 2016C021 C BE2016C021 C BE 2016C021C BE 2016C021 C BE2016C021 C BE 2016C021C BE 2016C021 I2 BE2016C021 I2 BE 2016C021I2
Authority
BE
Belgium
Application number
BE2016C021C
Other languages
French (fr)
Original Assignee
Merial Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Sas filed Critical Merial Sas
Publication of BE2016C021I2 publication Critical patent/BE2016C021I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BE2016C021C 2001-04-06 2016-04-26 BE2016C021I2 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0104737A FR2823222B1 (fr) 2001-04-06 2001-04-06 Vaccin contre le virus de la fievre du nil
PCT/FR2002/001200 WO2002081621A2 (fr) 2001-04-06 2002-04-05 Vaccin contre le virus de la fievre du nil

Publications (1)

Publication Number Publication Date
BE2016C021I2 true BE2016C021I2 (da) 2021-03-23

Family

ID=8862055

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2016C021C BE2016C021I2 (da) 2001-04-06 2016-04-26

Country Status (22)

Country Link
EP (2) EP1377660B1 (da)
JP (1) JP4426761B2 (da)
AU (1) AU2002307971B2 (da)
BE (1) BE2016C021I2 (da)
BR (1) BRPI0208896B1 (da)
CA (1) CA2448796C (da)
CY (2) CY1117676T1 (da)
DK (1) DK1377660T3 (da)
ES (2) ES2566044T3 (da)
FR (2) FR2823222B1 (da)
HK (2) HK1219412A1 (da)
HU (2) HU230122B1 (da)
IL (3) IL158204A0 (da)
LT (1) LTC1377660I2 (da)
LU (1) LU93048I2 (da)
MX (1) MXPA03008998A (da)
NL (1) NL300806I2 (da)
PL (2) PL207584B1 (da)
RU (1) RU2283138C2 (da)
SI (1) SI1377660T1 (da)
WO (1) WO2002081621A2 (da)
ZA (1) ZA200307620B (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002034119A2 (en) 2000-10-27 2002-05-02 Immuno-Rx, Inc. Vaccine immunotherapy for immune suppressed patients
HU228690B1 (en) 2001-07-27 2013-05-28 Wyeth Corp West nile vaccine
EP1572985A4 (en) * 2002-12-13 2008-03-19 Aventis Pasteur Inc ALVAC PRODUCTION ON AVIAN STEM CELLS
US8475808B2 (en) 2003-05-23 2013-07-02 Novartis Vaccines And Diagnostics, Inc. Immunogenic reagents from west nile virus
CA2582534A1 (en) 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
MY147379A (en) 2005-12-02 2012-11-30 Sinai School Medicine Chimeric viruses presenting non-native surface proteins and uses thereof
WO2010025469A1 (en) 2008-08-29 2010-03-04 Boehringer Ingelheim Vetmedica, Inc. West nile virus vaccine
US8591881B2 (en) 2009-02-05 2013-11-26 Mount Sinai School Of Medicine Chimeric Newcastle disease viruses and uses thereof
CN103200961B (zh) 2009-03-27 2017-10-27 中央研究院 抗病毒免疫的方法和组合物
ES2679043T3 (es) 2009-05-15 2018-08-21 Irx Therapeutics, Inc. Inmunoterapia de vacuna
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法
RU2506093C1 (ru) * 2012-12-06 2014-02-10 Государственное научное учреждение Якутский научно-исследовательский институт сельского хозяйства Российской академии сельскохозяйственных наук Способ специфической профилактики ринопневмонии, сальмонеллезного аборта и мыта лошадей ассоциированной вакциной в условиях табунного содержания
SG10201802982WA (en) 2013-03-14 2018-06-28 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
JP6857498B2 (ja) 2014-02-27 2021-04-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 癌を処置するための併用方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
NZ221790A (en) 1986-09-12 1990-07-26 Genentech Inc Method for the continuous production of a heterologous protein in a eukaryotic host cell
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
JP3602530B2 (ja) 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
US5382425A (en) 1992-01-13 1995-01-17 Syntro Corporation Recombinant swinepox virus
FR2702373B1 (fr) 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
EP0668355B1 (en) 1993-12-20 1999-04-07 Akzo Nobel N.V. Vaccine for the protection of horses against equine herpesvirus infection
FR2728794B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
FR2728795B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
EP0826063A1 (en) 1995-04-25 1998-03-04 Vical Incorporated Single-vial formulations of dna/lipid complexes
WO1998000166A1 (en) 1996-07-03 1998-01-08 Merial, Inc. Recombinant canine adenovirus (cav) containing exogenous dna
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
AU4992197A (en) 1996-10-11 1998-05-11 Regents Of The University Of California, The Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
IL131600A0 (en) * 1997-02-28 2001-01-28 Ora Vax Inc Chimeric flavivirus vaccines
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6294176B1 (en) 1998-07-10 2001-09-25 Schering-Plough Veterinary Corp. Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
US6416763B1 (en) * 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
CA2375320C (en) 1999-06-10 2013-02-19 Merial Dna vaccines for pets or for animals used in sports
FR2796397B1 (fr) 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines

Also Published As

Publication number Publication date
HUS1500047I1 (hu) 2017-03-28
SI1377660T1 (sl) 2016-05-31
ES2566044T3 (es) 2016-04-08
WO2002081621A2 (fr) 2002-10-17
BR0208896A (pt) 2004-07-20
RU2003132455A (ru) 2005-04-27
HU230122B1 (hu) 2015-08-28
HUP0401868A3 (en) 2011-06-28
MXPA03008998A (es) 2004-10-15
RU2283138C2 (ru) 2006-09-10
PL365210A1 (en) 2004-12-27
PL210306B1 (pl) 2011-12-30
EP1377660B1 (fr) 2016-01-13
JP2004531521A (ja) 2004-10-14
FR2823222A1 (fr) 2002-10-11
PL207584B1 (pl) 2011-01-31
CA2448796C (en) 2012-11-20
BRPI0208896B1 (pt) 2016-06-07
CY2016018I2 (el) 2016-12-14
EP2979705B1 (fr) 2019-10-23
NL300806I2 (da) 2016-06-09
CY2016018I1 (el) 2016-12-14
FR16C0014I2 (fr) 2016-09-09
ZA200307620B (en) 2005-07-27
LU93048I2 (fr) 2016-06-27
EP1377660A2 (fr) 2004-01-07
ES2767413T3 (es) 2020-06-17
CY1117676T1 (el) 2016-12-14
FR16C0014I1 (da) 2016-05-27
DK1377660T3 (da) 2016-03-29
CA2448796A1 (en) 2002-10-17
JP4426761B2 (ja) 2010-03-03
AU2002307971B2 (en) 2008-01-17
EP2979705A1 (fr) 2016-02-03
IL185263A0 (en) 2008-01-06
IL158204A (en) 2013-03-24
IL158204A0 (en) 2004-05-12
LTC1377660I2 (lt) 2017-04-25
WO2002081621A3 (fr) 2003-02-20
HK1061868A1 (zh) 2004-10-08
HK1219412A1 (zh) 2017-04-07
HUP0401868A2 (hu) 2004-12-28
FR2823222B1 (fr) 2004-02-06

Similar Documents

Publication Publication Date Title
BE2022C531I2 (da)
BE2022C502I2 (da)
BE2022C547I2 (da)
BE2017C056I2 (da)
BE2017C051I2 (da)
BE2017C050I2 (da)
BE2011C034I2 (da)
BE2007C047I2 (da)
AU2002307149A8 (da)
BRPI0209186B1 (da)
BRPI0204884B1 (da)
CH1379220H1 (da)
BE2016C021I2 (da)
BE2017C059I2 (da)
JP2002224972A5 (da)
BRPI0101486B8 (da)
JP2001285198A5 (da)
BRPI0210463A2 (da)
JP2002210074A5 (da)
AU2000280389A8 (da)
JP2002200552A5 (da)
JP2002222758A5 (da)
JP2002111743A5 (da)
JP2002011354A5 (da)
BRMU8103221U (da)